Bakuchiol is a plant-derived active that brands increasingly position as a gentler alternative to retinol. Before you build a product around it, two practical questions matter more than the marketing angle: where is bakuchiol allowed, and at what level? China added it to the Inventory of Existing Cosmetic Ingredients in China (IECIC) in a 2026 inventory update, with a stated safe use level of 1% in facial cosmetics, excluding formats that may create inhalation exposure. The European Union took a different route: bakuchiol is not listed in the prohibited or restricted annexes of Regulation (EC) No 1223/2009, so the concentration decision sits with your safety assessment rather than with a fixed legal ceiling. Those are not the same regulatory situation, and the difference determines how far one formula can travel between markets.
What is bakuchiol, and how is it related to retinol?
Bakuchiol (INCI name BAKUCHIOL, CAS 10309-37-2) is isolated from Psoralea corylifolia, a plant also known as babchi. Chemically it is a meroterpene, a terpene-phenol structure with no relationship to retinol, which is a diterpene alcohol. The two are not chemical relatives, and calling bakuchiol a "natural retinol" is simply inaccurate.
The comparison is functional rather than structural. In vitro work suggests bakuchiol may partially activate some of the same retinoic-acid-responsive gene pathways, and separate laboratory studies have looked at its antioxidant behavior and its effect on signals associated with visible redness. That is a research observation, not a product promise, and your copy should keep it phrased that way.
How strong is the evidence behind bakuchiol?
Better than for many botanical actives, and narrower than most brand decks suggest. The most frequently cited study, published in 2019, was a split-face randomized comparison: 0.5% bakuchiol applied twice daily versus 0.5% retinol applied once nightly, over twelve weeks, in a group of roughly forty-four participants. Both sides showed comparable improvement in the appearance of wrinkles and pigmentation, and the bakuchiol side reported less dryness and scaling.
Read that carefully before you quote it. It is one study, with a small sample, at one pair of concentrations, in one vehicle. It supports a measured statement about appearance and sensory tolerability. It does not support a general claim that bakuchiol behaves like retinol in every formula, and it is not a basis for any claim about skin structure or a skin condition.
Where is bakuchiol allowed, and at what concentration?
This is where product plans stall, because "not restricted" and "permitted up to a stated level" are two different regulatory positions.
| Market | Current status | What it means for your formula |
|---|---|---|
| China | Listed in the IECIC following a 2026 inventory update, with a safe use level of 1% for facial cosmetics, excluding products that may involve inhalation exposure | 1% is a hard design constraint. Sprays, mists and powder formats need a separate look because of the inhalation carve-out |
| European Union | Not listed in the prohibited or restricted annexes of Regulation (EC) No 1223/2009, and no committee opinion setting a specific concentration limit | No fixed ceiling, but the Responsible Person still has to justify the level in the Product Information File (PIF) and notify the product through the Cosmetic Products Notification Portal (CPNP) |
| United States | No pre-market approval step for an ingredient of this type | Safety substantiation and labeling responsibility sit with the brand, and claims still have to stay inside cosmetic territory |
Two consequences follow. First, if China is anywhere on your roadmap, 1% in facial products is the number the formula has to respect, even when your EU version could technically go higher. Second, an ingredient that is absent from the EU annexes is not an ingredient without obligations. Absence of a legal limit shifts the decision to your safety assessor, it does not remove it.
Why the raw material matters more than the percentage
Babchi seed oil naturally contains furocoumarins, including psoralen, a group associated with photosensitivity. The EU prohibits furocoumarins as such and sets an extremely low residual limit for sun protection and tanning products, in the order of 1 mg/kg. Cosmetic-grade bakuchiol is a purified single active isolated with the aim of removing those compounds, but the word "bakuchiol" on a specification sheet does not by itself confirm that residuals were controlled.
So when you review a Certificate of Analysis (COA), the bakuchiol assay is only the first line. Ask for:
- Residual furocoumarins and psoralen, with the test method stated rather than a bare "not detected"
- Residual solvents from the extraction or synthesis route
- Whether the material is plant-isolated or synthetic, and the botanical origin and part used if plant-isolated
- Stability data plus a recommended handling, storage and dosing window
What does bakuchiol need from a formulation?
It is lipophilic, so it needs an oil phase or a solubilizing system. Dropping it into a light aqueous gel usually ends in haze or crystallization on storage. Typical market use levels sit between 0.5% and 2%, and published evidence does not point to additional benefit above 2%. That band is formulation practice rather than regulatory permission: where a market states a lower level, the market wins.
Two further points are useful during development:
- Bakuchiol is more photostable than retinol, so it is typically workable in both daytime and nighttime products. That widens your routine design and removes the "PM only" constraint from the packaging copy.
- There are no known incompatibilities with niacinamide, vitamin C derivatives, hyaluronic acid, peptides or ceramides. "No known incompatibility" is not the same as "verified in your formula", so accelerated stability and packaging compatibility testing still apply.
Where the data is thin, say so. There is not enough evidence on use during pregnancy or breastfeeding to support any reassurance, so the honest approach is to leave that claim out and direct consumers to a qualified professional.
What can you claim, and what should you rewrite?
| Wording to avoid | Problem | Workable phrasing |
|---|---|---|
| A natural retinol | Structurally inaccurate | A plant-derived active studied alongside retinol |
| Erases wrinkles | Absolute outcome, unsupported | Helps improve the appearance of fine lines |
| Rebuilds the skin barrier | Implies a physiological action | Supports the look and feel of the skin barrier |
| Boosts collagen | Physiological claim outside cosmetic scope | Formulated to support the appearance of firmness |
| Gentle enough for everyone | Universal claim | Formulated for a gentler sensory profile at comparable use levels |
What should you confirm before you place an order?
- Which markets the SKU is going to, and whether the 1% facial level in China caps the whole range or only the China version
- The COA scope, including furocoumarin and psoralen residuals and the methods used
- Who writes and signs the safety assessment for the EU, and whether that person has seen the final concentration
- Whether the claim set on the artwork is supported by data you actually hold, market by market
- Stability and packaging compatibility results at the dose you plan to launch, not at a lower pilot dose
If you are scoping a bakuchiol line and want to pressure-test the concentration, claim set and market list against real production constraints, our technical team can review the brief with you before tooling and artwork are locked.